403
Sorry!!
Error! We're sorry, but the page you were
looking for doesn't exist.
Ocular Drug Delivery Devices Market To Hit USD 27.13B By 2032, Growing At 8.54% CAGR SNS Insider
(MENAFN- EIN Presswire)
Advancements in drug formulation technologies, enhanced bioavailability, and precision delivery mechanisms are reshaping therapeutic strategies across the ophthalmology sector. This rapid innovation is not only improving patient outcomes but also attracting significant investments and strategic collaborations from leading industry players.
With increasing R&D investments and favorable regulatory developments, the market is evolving into a critical arena for healthcare innovation. Executives and investors are encouraged to explore the strategic opportunities presented by this dynamic sector, which promises to revolutionize ocular therapeutics and drive significant value creation.
Get a Free Sample Report@
By Type: the ocular insert segment emerged as the dominant segment in the ocular drug delivery devices market in 2023
Ocular inserts are also commonly preferred for their controlled drug-release properties, which improve patient compliance by minimizing the frequency of administration required. This makes them especially useful in managing chronic conditions like glaucoma and diabetic macular edema, where continual delivery of the drug is imperative. Their capacity to provide medication directly to the eye has resulted in widespread use in ocular drug therapies. On the other hand, the topical segment is likely to witness the quickest growth, owing to increasing demand for non-invasive, convenient drug delivery technologies that are user-friendly and deliver comfort and convenience to patients.
By Drug Forms: in 2023, the solution segment dominated the ocular drug delivery devices market, accounting for nearly 40% of the market share.
Solutions are the most extensively utilized form in ocular drug delivery because they are easy to apply and can effectively treat ocular diseases. Solutions are especially useful in treating diseases such as glaucoma and refractive errors, which need frequent dosing. The injectable drug delivery devices segment is projected to witness the strongest growth, however. These devices enable accurate and controlled administration of the drug, providing improved treatment results. They are becoming more popular for conditions such as diabetic retinopathy and macular degeneration, for which drug delivery to the retina targeted and prolonged is essential to treat the disease and avoid further loss of vision.
Glaucoma remained the leading disease type in the ocular drug delivery devices market, driving a significant share of the demand for targeted treatments.
Glaucoma dominated the market for ocular drug delivery devices in 2023, with its increasing prevalence, particularly among the elderly, propelling it. The use of sustained-release therapy and the requirement for more effective treatments to control intraocular pressure is central to the growth of the segment. Diabetic macular edema (DME) was the fastest-growing disease category, supported by the rising global prevalence of diabetes. This increased incidence has prompted a larger market for innovative drug delivery treatments against retinal ailments, thus facilitating swift innovation in treatments and therapeutics for patients with DME.
By End User: Hospital pharmacies held the largest share of the ocular drug delivery devices market in 2023
They are the major dispensers of such devices since they are close to patients who need complicated ocular treatments. Hospitals offer varying services, from surgical procedures to regular eye care, and hence they are the major consumers of ocular drug delivery systems. The online pharmacies segment is, however, growing at the fastest rate. The ease and availability of buying ocular medicines from online sites, particularly with the advent of e-commerce, have been responsible for the increasing popularity of this medium.
Key Players in Ocular Drug Delivery Devices Market
.Invacare Corporation (TDX SP2 Power Wheelchair, Rollite Rollator Walker)
.Sunrise Medical (Quickie Q500 M Power Wheelchair, Airgo Comfort-Plus Lightweight Rollator)
.Alimera Sciences (Iluvien, Yutiq)
.Regeneron Pharmaceuticals (EYLEA, Ozurdex)
.Novartis (Lucentis, Beovu
.Genentech (Roche) (Avastin, Lucentis)
.AbbVie (Restasis, Ozurdex)
.Bausch Health (Xipere, Visudyne)
.EyePoint Pharmaceuticals (Yutiq, DEXYCU)
.Envisia Therapeutics (ENV515, ENV105)
.Lux Biosciences (LX211, Visudyne)
.Eyenovia (MicroStat, Optejet)
.Apellis Pharmaceuticals (Empaveli, Syfovre)
.Kodiak Sciences (KSI-301, KSI-201)
.Ionis Pharmaceuticals (IONIS-FXIRx, IONIS-TTRRx)
.Alcon (Systane, AcrySof Natural)
.Ophthotech Corporation (now IVERIC Bio) (Zimura, IPR-001)
.Santen Pharmaceutical (Ikervis, Diquas)
.Imprimis Pharmaceuticals (MiStat, Dexamethasone ophthalmic injectable)
.TearLab Corporation (TearLab Osmolarity System, TearLab Diagnostic System)
.Medtronic (Retisert, Micropump)
Buy Full Research Report on Ocular Drug Delivery Devices Market 2024-2032 @
Regional Analysis: North America led the ocular drug delivery devices market in 2023, capturing around 42% of the global market share.
The dominance of the region can be explained by its advanced healthcare infrastructure, a high adoption rate of new medical technologies, and an increasing prevalence of eye diseases like glaucoma and diabetic retinopathy. In addition, the region enjoys a robust presence of leading industry players and increasing emphasis on the creation of innovative drug delivery systems.
The Asia-Pacific market is the fastest-growing market, with growth spurred by accelerated healthcare growth and growing investments in healthcare infrastructure. China and India are experiencing a boom in the incidence of eye diseases, as well as improved access to affordable eye care services, which is boosting demand for ocular drug delivery devices. Furthermore, the region's growing awareness of eye health and the expanding geriatric population are also anticipated to drive market growth.
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
6. Competitive Landscape
7. Ocular Drug Delivery Devices Market by Type
8. Ocular Drug Delivery Devices Market by Drug Forms
9. Ocular Drug Delivery Devices Market by Disease Type
10. Ocular Drug Delivery Devices Market by End User
10. Regional Analysis
11. Company Profiles
12. Use Cases and Best Practices
13. Conclusion
For further insights and customized research on the Ocular Drug Delivery Devices Market, contact @
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Ocular Drug Delivery Devices Market
Innovative ocular drug delivery solutions drive growth from USD 13.03B in 2023 to USD 27.13B by 2032, unlocking new strategic opportunities.
Transformative advancements in ocular drug delivery are reshaping treatment paradigms and fueling unprecedented market growth, offering lucrative returns for strategic investors.” - SNS InsiderAUSTIN, TX, UNITED STATES, February 19, 2025 /EINPresswire / -- According to Research by SNS Insider, the global Ocular Drug Delivery Devices Market is on a transformative journey-valued at USD 13.03 billion in 2023 and projected to reach USD 27.13 billion by 2032, growing at a robust CAGR of 8.54% from 2024 to 2032.Advancements in drug formulation technologies, enhanced bioavailability, and precision delivery mechanisms are reshaping therapeutic strategies across the ophthalmology sector. This rapid innovation is not only improving patient outcomes but also attracting significant investments and strategic collaborations from leading industry players.
With increasing R&D investments and favorable regulatory developments, the market is evolving into a critical arena for healthcare innovation. Executives and investors are encouraged to explore the strategic opportunities presented by this dynamic sector, which promises to revolutionize ocular therapeutics and drive significant value creation.
Get a Free Sample Report@
By Type: the ocular insert segment emerged as the dominant segment in the ocular drug delivery devices market in 2023
Ocular inserts are also commonly preferred for their controlled drug-release properties, which improve patient compliance by minimizing the frequency of administration required. This makes them especially useful in managing chronic conditions like glaucoma and diabetic macular edema, where continual delivery of the drug is imperative. Their capacity to provide medication directly to the eye has resulted in widespread use in ocular drug therapies. On the other hand, the topical segment is likely to witness the quickest growth, owing to increasing demand for non-invasive, convenient drug delivery technologies that are user-friendly and deliver comfort and convenience to patients.
By Drug Forms: in 2023, the solution segment dominated the ocular drug delivery devices market, accounting for nearly 40% of the market share.
Solutions are the most extensively utilized form in ocular drug delivery because they are easy to apply and can effectively treat ocular diseases. Solutions are especially useful in treating diseases such as glaucoma and refractive errors, which need frequent dosing. The injectable drug delivery devices segment is projected to witness the strongest growth, however. These devices enable accurate and controlled administration of the drug, providing improved treatment results. They are becoming more popular for conditions such as diabetic retinopathy and macular degeneration, for which drug delivery to the retina targeted and prolonged is essential to treat the disease and avoid further loss of vision.
Glaucoma remained the leading disease type in the ocular drug delivery devices market, driving a significant share of the demand for targeted treatments.
Glaucoma dominated the market for ocular drug delivery devices in 2023, with its increasing prevalence, particularly among the elderly, propelling it. The use of sustained-release therapy and the requirement for more effective treatments to control intraocular pressure is central to the growth of the segment. Diabetic macular edema (DME) was the fastest-growing disease category, supported by the rising global prevalence of diabetes. This increased incidence has prompted a larger market for innovative drug delivery treatments against retinal ailments, thus facilitating swift innovation in treatments and therapeutics for patients with DME.
By End User: Hospital pharmacies held the largest share of the ocular drug delivery devices market in 2023
They are the major dispensers of such devices since they are close to patients who need complicated ocular treatments. Hospitals offer varying services, from surgical procedures to regular eye care, and hence they are the major consumers of ocular drug delivery systems. The online pharmacies segment is, however, growing at the fastest rate. The ease and availability of buying ocular medicines from online sites, particularly with the advent of e-commerce, have been responsible for the increasing popularity of this medium.
Key Players in Ocular Drug Delivery Devices Market
.Invacare Corporation (TDX SP2 Power Wheelchair, Rollite Rollator Walker)
.Sunrise Medical (Quickie Q500 M Power Wheelchair, Airgo Comfort-Plus Lightweight Rollator)
.Alimera Sciences (Iluvien, Yutiq)
.Regeneron Pharmaceuticals (EYLEA, Ozurdex)
.Novartis (Lucentis, Beovu
.Genentech (Roche) (Avastin, Lucentis)
.AbbVie (Restasis, Ozurdex)
.Bausch Health (Xipere, Visudyne)
.EyePoint Pharmaceuticals (Yutiq, DEXYCU)
.Envisia Therapeutics (ENV515, ENV105)
.Lux Biosciences (LX211, Visudyne)
.Eyenovia (MicroStat, Optejet)
.Apellis Pharmaceuticals (Empaveli, Syfovre)
.Kodiak Sciences (KSI-301, KSI-201)
.Ionis Pharmaceuticals (IONIS-FXIRx, IONIS-TTRRx)
.Alcon (Systane, AcrySof Natural)
.Ophthotech Corporation (now IVERIC Bio) (Zimura, IPR-001)
.Santen Pharmaceutical (Ikervis, Diquas)
.Imprimis Pharmaceuticals (MiStat, Dexamethasone ophthalmic injectable)
.TearLab Corporation (TearLab Osmolarity System, TearLab Diagnostic System)
.Medtronic (Retisert, Micropump)
Buy Full Research Report on Ocular Drug Delivery Devices Market 2024-2032 @
Regional Analysis: North America led the ocular drug delivery devices market in 2023, capturing around 42% of the global market share.
The dominance of the region can be explained by its advanced healthcare infrastructure, a high adoption rate of new medical technologies, and an increasing prevalence of eye diseases like glaucoma and diabetic retinopathy. In addition, the region enjoys a robust presence of leading industry players and increasing emphasis on the creation of innovative drug delivery systems.
The Asia-Pacific market is the fastest-growing market, with growth spurred by accelerated healthcare growth and growing investments in healthcare infrastructure. China and India are experiencing a boom in the incidence of eye diseases, as well as improved access to affordable eye care services, which is boosting demand for ocular drug delivery devices. Furthermore, the region's growing awareness of eye health and the expanding geriatric population are also anticipated to drive market growth.
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
6. Competitive Landscape
7. Ocular Drug Delivery Devices Market by Type
8. Ocular Drug Delivery Devices Market by Drug Forms
9. Ocular Drug Delivery Devices Market by Disease Type
10. Ocular Drug Delivery Devices Market by End User
10. Regional Analysis
11. Company Profiles
12. Use Cases and Best Practices
13. Conclusion
For further insights and customized research on the Ocular Drug Delivery Devices Market, contact @
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Jagney Dave
SNS Insider Pvt. Ltd
+1 315-636-4242
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
Comments
No comment